OpenLB
Open Library of Bioscience

Do not de-escalate oncology care in oropharyngeal cancer routinely.

Abstract

No abstract text available.

References

1. Ilmarinen T, Keski-Säntti H, Markkanen-Leppänen M, et al. De-escalation of post-treatment surveillance in oropharyngeal cancer. Head Neck. 2019;41(5):1457-1462.
2. Huang SH, Perez-Ordonez B, Weinreb I, et al. Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol. 2013;49(1):79-85.
3. Trosman SJ, Koyfman SA, Ward MC, et al. Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. JAMA Otolaryngol Head Neck Surg. 2015;141(5):457-462.
4. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24-35.
5. O'Sullivan B, Huang SH, Su J, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the international collaboration on Oropharyngeal cancer network for staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17(4):440-451.
6. Mirghani H, Blanchard P. Treatment de-escalation for HPV-driven oropharyngeal cancer: where do we stand? Clin Transl Radiat Oncol. 2017;8:4-11.
7. Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393(10166):51-60.
8. Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40-50.
9. Dong Y, Ridge JA, Li T, et al. Long-term toxicities in 10-year survivors of radiation treatment for head and neck cancer. Oral Oncol. 2017;71:122-128.
10. Goldsmith T, Jacobson MC. Managing the late effects of chemoradiation on swallowing: bolstering the beginning, minding the middle, and cocreating the end. Curr Opin Otolaryngol Head Neck Surg. 2018;26(3):180-187.
11. Trinidade A, Kothari P, Andreou Z, Hewitt RJD, O'Flynn P. Follow-up in head and neck cancer: patients' perspective. Int J Health Care Qual Assur. 2012;25(2):145-149.
12. Meregaglia M, Cairns J, Alfieri S, et al. Eliciting preferences for clinical follow-up in patients with head and neck cancer using best-worst scaling. Value Health. 2017;20(6):799-808.
13. Mueller SA, Riggauer J, Elicin O, et al. Patients' preferences concerning follow-up after curative head and neck cancer treatment: a cross-sectional pilot study. Head Neck. 2019;41(7):2174-2181. https://doi.org/10.1002/hed.25686.
14. Brennan KE, Hall SF, Yoo J, et al. Routine follow-up care after curative treatment of head and neck cancer: a survey of patients' needs and preferences for healthcare services. Eur J Cancer Care (Engl). 2019;28(2):e12993.

MeSH Term